Literature DB >> 19487649

Remyelination capacity of the MS brain decreases with disease chronicity.

T Goldschmidt1, J Antel, F B König, W Brück, T Kuhlmann.   

Abstract

OBJECTIVE: To analyze and compare the extent of remyelination in lesions from patients with multiple sclerosis (MS) who have a short (early MS lesions) or a long (chronic MS lesions) disease duration and to determine the influence of anatomic localization on the extent of remyelination. In early MS lesions, remyelination has been described as a relatively frequent event, in contrast to chronic MS lesions, where remyelination is absent or limited to the lesion border in the majority of lesions. However, no studies have been published that have quantified and compared the extent of remyelination in early and chronic MS lesions.
METHODS: We analyzed the occurrence of remyelination in 52 biopsies from 51 patients (early MS) and in 174 lesions from 36 autopsy cases (chronic MS) by immunohistochemistry for myelin proteins, and correlated our findings with anatomic localization, sex, age, and disease duration.
RESULTS: Significantly more lesions were remyelinated in early than in chronic MS (80.7% vs 60%). In chronic MS, subcortical lesions showed more extensive remyelination than periventricular lesions. The majority of cerebellar lesions were completely demyelinated.
CONCLUSION: In summary, our data demonstrate that remyelination is a frequent event in early multiple sclerosis lesions. Furthermore, the anatomic localization of a lesion might influence the extent of remyelination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19487649     DOI: 10.1212/WNL.0b013e3181a8260a

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  123 in total

Review 1.  Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.

Authors:  Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

2.  Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions.

Authors:  Martina Absinta; Pascal Sati; Matthew Schindler; Emily C Leibovitch; Joan Ohayon; Tianxia Wu; Alessandro Meani; Massimo Filippi; Steven Jacobson; Irene C M Cortese; Daniel S Reich
Journal:  J Clin Invest       Date:  2016-06-06       Impact factor: 14.808

Review 3.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

4.  2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination.

Authors:  Ana Feliú; Itziar Bonilla Del Río; Francisco Javier Carrillo-Salinas; Gloria Hernández-Torres; Leyre Mestre; Nagore Puente; Silvia Ortega-Gutiérrez; Maria L López-Rodríguez; Pedro Grandes; Miriam Mecha; Carmen Guaza
Journal:  J Neurosci       Date:  2017-07-27       Impact factor: 6.167

Review 5.  Immunosenescence of microglia and macrophages: impact on the ageing central nervous system.

Authors:  Khalil S Rawji; Manoj K Mishra; Nathan J Michaels; Serge Rivest; Peter K Stys; V Wee Yong
Journal:  Brain       Date:  2016-01-29       Impact factor: 13.501

6.  Aging-Exacerbated Acute Axon and Myelin Injury Is Associated with Microglia-Derived Reactive Oxygen Species and Is Alleviated by the Generic Medication Indapamide.

Authors:  Nathan J Michaels; Kennedy Lemmon; Jason R Plemel; Samuel K Jensen; Manoj K Mishra; Dennis Brown; Khalil S Rawji; Marcus Koch; V Wee Yong
Journal:  J Neurosci       Date:  2020-10-15       Impact factor: 6.167

Review 7.  Oligodendrocytes: biology and pathology.

Authors:  Monika Bradl; Hans Lassmann
Journal:  Acta Neuropathol       Date:  2009-10-22       Impact factor: 17.088

8.  Cortical remyelination: a new target for repair therapies in multiple sclerosis.

Authors:  Ansi Chang; Susan M Staugaitis; Ranjan Dutta; Courtney E Batt; Kathryn E Easley; Anthony M Chomyk; V Wee Yong; Robert J Fox; Grahame J Kidd; Bruce D Trapp
Journal:  Ann Neurol       Date:  2012-10-17       Impact factor: 10.422

Review 9.  Remyelination therapy for multiple sclerosis.

Authors:  Michael B Keough; V Wee Yong
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

10.  MHC mismatch results in neural progenitor cell rejection following spinal cord transplantation in a model of viral-induced demyelination.

Authors:  Jason G Weinger; Brian M Weist; Warren C Plaisted; Suzi M Klaus; Craig M Walsh; Thomas E Lane
Journal:  Stem Cells       Date:  2012-11       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.